Background: Bilastine, a novel non-sedating second-generation H antihistamine, has been approved in most European countries since 2010. This study aimed to evaluate the superiority of bilastine over placebo in Japanese patients with perennial allergic rhinitis (PAR).
Methods: This randomized, double-blind, placebo-controlled, parallel-group, phase III study (trial registration number JapicCTI-142600) evaluated the effect of a 2-week treatment period with bilastine (20 mg once daily), fexofenadine (60 mg twice daily), or a matched placebo (double dummy) in patients with PAR. All patients were instructed to record individual nasal and ocular symptoms in diaries daily. The primary endpoint was the mean change in total nasal symptom scores (TNSS) from baseline to Week 2 (Days 10-13).
Results: A total of 765 patients were randomly allocated to receive bilastine, fexofenadine, or placebo (256, 254, and 255 patients, respectively). The mean change in TNSS from baseline at Week 2 was significantly decreased by bilastine (-0.98) compared to placebo (-0.63, P = 0.023). Bilastine and fexofenadine showed no significant difference in the primary endpoint. However, the mean change in TNSS from baseline on Day 1 was more significantly decreased by bilastine (-0.99) than by placebo (-0.28, P < 0.001) or fexofenadine (-0.62, P = 0.032). The active drugs also improved instantaneous TNSS 1 h after the first and before the second drug administration on Day 1 (P < 0.05). The study drugs were well tolerated.
Conclusions: After 2-week treatment period, bilastine 20 mg once daily was effective and tolerable in Japanese patients with PAR, and exhibited a rapid onset of action.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.alit.2016.05.014 | DOI Listing |
J Allergy Clin Immunol Pract
December 2024
Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China. Electronic address:
Background: Moderate to severe persistent allergic rhinitis (AR) poses a substantial socioeconomic burden.
Objectives: We aimed to establish the superiority of bencycloquidium bromide (BCQB) nasal spray and BCQB combined with mometasone furoate nasal spray (MFNS) over MFNS alone in adults with moderate to severe persistent AR.
Methods: In this multicenter, randomized, controlled clinical trial (NCT05038202), adults with moderate to severe persistent AR were randomly assigned to receive BCQB, MFNS, or a combination treatment for 4-week periods.
In Vivo
December 2024
Department of Otolaryngology, Head and Neck Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, R.O.C.
Background/aim: This study evaluated the outcomes of combining submucosal turbinectomy with extensive disruption of the pterygopalatine ganglionic efferent nerve fibers through a minimucosal incision in patients with intractable rhinitis, irrespective of their dependency on the posterior nasal nerve.
Patients And Methods: We describe an endoscopic extended neurectomy procedure performed via a minimucosal pocket. The primary outcome measures included the Total Nasal Symptom Score (TNSS), Visual Analog Scale (VAS) score, and runny nose and nasal obstruction subdomains of the Sino-Nasal Outcome Test-22 (SNOT-22), which were assessed pre-procedure and at 3 and 6 months post-procedure.
Ann Otol Rhinol Laryngol
December 2024
Department of Otorhinolaryngology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Objective: Soluble fibrinogen-like protein 2 (sFGL2) may be involved in the pathology and progression of allergic rhinitis (AR) through regulating T-helper (Th)2 cell response. This study aimed to explore the ability of sFGL2 to estimate outcomes in AR patients.
Methods: sFGL2 was detected in the serum sample of 119 AR patients at baseline and 20 healthy controls (HCs) after enrollment by enzyme-linked immunosorbent assay.
Front Immunol
November 2024
Department of Respiratory and Critical Care Medicine, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, China.
Background: Numerous studies have established that probiotics or prebiotics can relieve the symptoms of allergic rhinitis (AR), but their mechanism of action remain underexplored. This study aimed to observe the clinical efficacy of probiotics combined with prebiotics in seasonal AR patients and explore their underlying mechanisms.
Methods: We conducted a prospective, randomized, double-blind, placebo-controlled clinical trial.
Ann Allergy Asthma Immunol
November 2024
Allergy Research Unit, Kingston Health Sciences Centre - Kingston General Hospital Site, Kingston, Ontario, Canada; Department of Medicine, Queen's University, Kingston, Ontario, Canada; Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada. Electronic address:
Background: Previous studies have defined clinical phenotypes of allergic rhinitis (AR) after allergen exposure using the time course of the total nasal symptom score (TNSS).
Objective: To validate previously proposed AR phenotypes across different allergens (birch, grass, ragweed, and house dust mite) after exposure in the environmental exposure unit.
Methods: The Analyzing Phenotypes Post-Exposure in Allergic Rhinitis (APPEAR) database comprises 153 participants from environmental exposure unit studies conducted between 2010 and 2021 by Kingston Allergy Research.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!